141 related articles for article (PubMed ID: 31929425)
1. Association of More Intensive Induction With Less Acute Rejection Following Intestinal Transplantation: Results of 445 Consecutive Cases From a Single Center.
Vianna R; Farag A; Gaynor JJ; Selvaggi G; Tekin A; Garcia J; Beduschi T
Transplantation; 2020 Oct; 104(10):2166-2178. PubMed ID: 31929425
[TBL] [Abstract][Full Text] [Related]
2. Intestinal and multivisceral transplantation immunosuppression protocols--literature review.
Trevizol AP; David AI; Dias ER; Mantovani D; Pécora R; D'Albuquerque LA
Transplant Proc; 2012 Oct; 44(8):2445-8. PubMed ID: 23026616
[TBL] [Abstract][Full Text] [Related]
3. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
[TBL] [Abstract][Full Text] [Related]
4. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation.
Vianna RM; Mangus RS; Fridell JA; Weigman S; Kazimi M; Tector J
Transplantation; 2008 May; 85(9):1290-3. PubMed ID: 18475186
[TBL] [Abstract][Full Text] [Related]
5. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
[TBL] [Abstract][Full Text] [Related]
6. Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients.
Laftavi MR; Pankewycz O; Feng L; Said M; Patel S
Immunol Invest; 2015; 44(4):373-84. PubMed ID: 25942348
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP
Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773
[TBL] [Abstract][Full Text] [Related]
8. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
Saull HE; Enderby CY; Gonwa TA; Wadei HM
Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
[TBL] [Abstract][Full Text] [Related]
9. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 2014 Data Report: Intestine.
Cai J; Wu G; Qing A; Everly M; Cheng E; Terasaki P
Clin Transpl; 2014; ():33-47. PubMed ID: 26281125
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction
.
Descourouez JL; Jorgenson MR; Parajuli S; Mandelbrot DA; Leverson GE; Odorico JS; Redfield RR
Clin Nephrol; 2020 Feb; 93(2):77-84. PubMed ID: 31670651
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants.
Lentine KL; Schnitzler MA; Xiao H; Brennan DC
Trials; 2015 Aug; 16():365. PubMed ID: 26285695
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab Induction Is Associated With Equalization of Graft Outcomes Between Elderly and Nonelderly Kidney Transplant Recipients: A Single-Center Report.
DeLeonibus A; Mitro G; Brooks J; Rees M; Ortiz J
Exp Clin Transplant; 2020 Jun; 18(3):284-291. PubMed ID: 31050614
[TBL] [Abstract][Full Text] [Related]
15. Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction.
Kubal CA; Mangus RS; Saxena R; Lobashevsky A; Higgins N; Agarwal A; Fridell JA; Tector AJ
Transplantation; 2014 Jan; 97(1):56-63. PubMed ID: 24030603
[TBL] [Abstract][Full Text] [Related]
16. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
Cheng EY; Kaneku H; Farmer DG
Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience.
Yang JW; Wang JN; Men TY; Zhang XM; Li XD; Shen B; Li GY; Chen DD
Ann Transplant; 2014 Jun; 19():277-82. PubMed ID: 24906405
[TBL] [Abstract][Full Text] [Related]
20. A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation.
Abu-Elmagd KM; Costa G; Bond GJ; Soltys K; Martin L; Koritsky DA; Cunha-Melo JR; Sogawa H; Irish W; Tzakis A; Mazariegos G
Clin Transpl; 2012; ():155-66. PubMed ID: 23721018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
